Research Radartracking 4 published studies · 1 human · 2 clinical trials · 2 cancer pages · updated Jun 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “embryonal rhabdomyosarcoma”.
1 of 4 studies
Case reportTrialReported positiveLimited evidenceTier 3 · early humann = 2

Primary ovarian rhabdomyosarcoma in children

Pediatric surgery international · May 2008 · case reports

CyclophosphamideVincristineDoxorubicinovarian rhabdomyosarcomaalveolar rhabdomyosarcomaembryonal rhabdomyosarcoma

This report describes two children with very rare primary ovarian rhabdomyosarcoma. After complete surgical removal, both received chemotherapy with vincristine, doxorubicin, and cyclophosphamide and had a good response. Both patients were alive 8 and 9 months after surgery.

Key findings
  • Two pediatric cases of primary ovarian rhabdomyosarcoma were described.
  • Both patients underwent complete resection of the primary tumor.
  • Both received vincristine, doxorubicin, and cyclophosphamide chemotherapy.
  • The abstract reports a good response to therapy and survival at 8 and 9 months post-operatively.
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..

Describes management of a rare ovarian cancer in children, including chemotherapy, but does not isolate the effect of any single compound.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed